{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-22-000064","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.346957+00:00","generated_at":"2026-06-22T03:11:52.758882+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023","bullets":["Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.","Cash & investments $590.5M as of Sep 30, 2022, down $24.7M from Dec 31, 2021.","Collaboration revenue fell to $1.3M (Q3 2022) from $20.9M (Q3 2021) on no GSK milestones.","Rosnilimab Phase 2 alopecia areata top-line data expected Q1 2023; ANB032 IND Q4 2022.","Zejula royalty sale to DRI for up to $45M ($35M upfront); GSK earned $5M milestone for cobolimab Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-22-000064","json":"https://secwatch.observer/filing/0001370053-22-000064.json","markdown":"https://secwatch.observer/filing/0001370053-22-000064.md","text":"https://secwatch.observer/filing/0001370053-22-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/0001370053-22-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/anab-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:11:52.758882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"035566b15ca817a5e61c0170c6249accaff13073","claim":"ANAPTYSBIO, INC reported financial results for three and nine months ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/0001370053-22-000064-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}